Your browser doesn't support javascript.
loading
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Johnston, Stephen; Basik, Mark; Hegg, Roberto; Lausoontornsiri, Wirote; Grzeda, Lukasz; Clemons, Mark; Dreosti, Lydia; Mann, Helen; Stuart, Mary; Cristofanilli, Massimo.
Afiliação
  • Johnston S; The Royal Marsden NHS Foundation Trust, The Royal Marsden Hospital, Fulham Road, Chelsea, London, SW3 6JJ, UK. Stephen.Johnston@rmh.nhs.uk.
  • Basik M; Jewish General Hospital, Montreal, Canada.
  • Hegg R; Hospital Perola Byington, São Paulo, Brazil.
  • Lausoontornsiri W; National Cancer Institute of Thailand, Bangkok, Thailand.
  • Grzeda L; Magodent Sp. z o.o. Grupa Lux Med, Warsaw, Poland.
  • Clemons M; The Ottawa Hospital Cancer Center, Ottawa, Canada.
  • Dreosti L; University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa.
  • Mann H; AstraZeneca, Macclesfield, UK.
  • Stuart M; AstraZeneca, Macclesfield, UK.
  • Cristofanilli M; Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Breast Cancer Res Treat ; 160(1): 91-99, 2016 11.
Article em En | MEDLINE | ID: mdl-27654971
Assuntos
Palavras-chave
Buscar no Google
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Buscar no Google
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article